Our systematic review and meta-analyses of real-world evidence suggested that SGLT2 inhibitors were associated with reduced risk of pneumonia, pneumonia-related mortality, and sepsis. This evidence concerns the gene SLC5A2 and susceptibility to pneumonia measurement.